Health And Pharma News

The latest health and pharma stories, each synthesized from multiple sources with added background and context.

AbbVie Secures FDA Approval for Juvmo, First D1/D5 Agonist for Parkinson's

AbbVie received FDA approval on Friday for tavapadon, branded as Juvmo, the first selective D1/D5 receptor agonist for adults with Parkinson's disease. The approval validates the company's $8.7 billion acquisition of Cerevel Therapeutics, which closed in August 2024. Juvmo is priced at $4,900 per 30-day supply and is expected to launch in the U.S. next month. While the deal's flagship asset, emraclidine, failed in schizophrenia trials in 2025, Juvmo's success provides a new growth avenue for AbbVie's neuroscience division.

7 hours ago•Source: Fierce Pharma

Novo Nordisk rebrands GLP-1s from medical treatment to lifestyle product

health-and-pharma

2.45 min•13 hours ago

Novo Nordisk rebrands GLP-1s from medical treatment to lifestyle product

Novo Nordisk is shifting its marketing of GLP-1 drugs from medical necessity to lifestyle enhancement, using slogans like 'Live lighter' and referring to users as 'customers' rather than 'patients.' While these drugs offer significant weight loss and health benefits, experts warn that this consumer-focused approach ignores serious side effects, legal risks for prescribers, and the high costs that strain healthcare budgets.

via STAT

Featured Health And Pharma Stories

AbbVie Secures FDA Approval for Juvmo, First D1/D5 Agonist for Parkinson's

Novo Nordisk rebrands GLP-1s from medical treatment to lifestyle product

More Health And Pharma Stories